RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources

PURPOSE: To test the cost-effectiveness of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment in patients with metastatic colorectal cancer (mCRC) from a Chinese medical insurance perspective. RESULTS: Baseline analysis showed that the addition of cetuximab inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Bin, Yao, Yuan, Zhang, Ke, Ma, Xuezhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642627/
https://www.ncbi.nlm.nih.gov/pubmed/29050352
http://dx.doi.org/10.18632/oncotarget.17029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642627/
https://www.ncbi.nlm.nih.gov/pubmed/29050352
http://dx.doi.org/10.18632/oncotarget.17029

Ejemplares similares